Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.17 | N/A | +16.01% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.17 | N/A | +16.01% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management highlighted the positive EPS surprise as a sign of progress. They remain focused on advancing their product pipeline.
Management expressed satisfaction with the EPS performance despite no revenue figures.
They emphasized ongoing efforts in their pipeline development.
Mirum Pharmaceutical's earnings report showed a better-than-expected EPS, which contributed to a 6.15% increase in stock price. The lack of revenue figures means investors are still waiting for more comprehensive financial insights. Management's focus on pipeline development suggests they are looking to build on this momentum in the future.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENTERPRISE PRODS PAR
May 2, 2022